Free Trial

Prima BioMed (IMMP) Competitors

Prima BioMed logo
$2.04 -0.03 (-1.45%)
Closing price 04:00 PM Eastern
Extended Trading
$2.04 +0.00 (+0.25%)
As of 04:18 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IMMP vs. SYRE, PHVS, NBTX, PRAX, RLAY, SPRY, DNTH, LENZ, AMPH, and UPB

Should you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Spyre Therapeutics (SYRE), Pharvaris (PHVS), Nanobiotix (NBTX), Praxis Precision Medicines (PRAX), Relay Therapeutics (RLAY), ARS Pharmaceuticals (SPRY), Dianthus Therapeutics (DNTH), LENZ Therapeutics (LENZ), Amphastar Pharmaceuticals (AMPH), and Upstream Bio (UPB). These companies are all part of the "pharmaceutical products" industry.

Prima BioMed vs. Its Competitors

Prima BioMed (NASDAQ:IMMP) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Prima BioMed has higher revenue and earnings than Spyre Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prima BioMed$6.69M44.88-$39.78MN/AN/A
Spyre Therapeutics$890K1,594.15-$208.02M-$3.40-6.91

Prima BioMed has a beta of 1.87, meaning that its stock price is 87% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.9, meaning that its stock price is 190% more volatile than the S&P 500.

Prima BioMed's return on equity of 0.00% beat Spyre Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Prima BioMedN/A N/A N/A
Spyre Therapeutics N/A -71.30%-38.69%

2.3% of Prima BioMed shares are held by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are held by institutional investors. 3.1% of Prima BioMed shares are held by insiders. Comparatively, 6.2% of Spyre Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Spyre Therapeutics had 15 more articles in the media than Prima BioMed. MarketBeat recorded 17 mentions for Spyre Therapeutics and 2 mentions for Prima BioMed. Spyre Therapeutics' average media sentiment score of 0.64 beat Prima BioMed's score of 0.00 indicating that Spyre Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Prima BioMed
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Spyre Therapeutics
3 Very Positive mention(s)
4 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive

Prima BioMed currently has a consensus target price of $7.00, indicating a potential upside of 243.14%. Spyre Therapeutics has a consensus target price of $54.29, indicating a potential upside of 131.10%. Given Prima BioMed's higher possible upside, research analysts plainly believe Prima BioMed is more favorable than Spyre Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Prima BioMed
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Spyre Therapeutics
1 Sell rating(s)
0 Hold rating(s)
7 Buy rating(s)
2 Strong Buy rating(s)
3.00

Summary

Spyre Therapeutics beats Prima BioMed on 9 of the 14 factors compared between the two stocks.

Get Prima BioMed News Delivered to You Automatically

Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IMMP vs. The Competition

MetricPrima BioMedMED IndustryMedical SectorNASDAQ Exchange
Market Cap$300.27M$3.46B$6.17B$10.68B
Dividend YieldN/A2.27%5.72%4.83%
P/E RatioN/A23.2129.4127.38
Price / Sales44.88479.02588.00132.78
Price / CashN/A45.2825.8230.35
Price / Book3.2410.5412.496.68
Net Income-$39.78M-$52.62M$3.32B$276.27M
7 Day Performance2.51%4.90%2.38%0.95%
1 Month Performance26.71%15.97%8.71%3.92%
1 Year Performance2.51%14.17%61.90%36.33%

Prima BioMed Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IMMP
Prima BioMed
0.7085 of 5 stars
$2.04
-1.4%
$7.00
+243.1%
+4.0%$300.27M$6.69M0.002,021News Coverage
High Trading Volume
SYRE
Spyre Therapeutics
2.916 of 5 stars
$18.92
-1.1%
$54.29
+186.9%
-31.4%$1.16B$890K-5.5673
PHVS
Pharvaris
2.6814 of 5 stars
$22.07
+0.4%
$32.60
+47.7%
-0.4%$1.15BN/A-6.5730Positive News
Analyst Revision
NBTX
Nanobiotix
0.8298 of 5 stars
$30.31
+28.4%
$11.00
-63.7%
+441.2%$1.13B$39.18M0.00100Short Interest ↑
PRAX
Praxis Precision Medicines
2.5306 of 5 stars
$52.34
-1.7%
$85.56
+63.5%
+159.5%$1.12B$8.55M-4.26110Analyst Forecast
RLAY
Relay Therapeutics
2.2001 of 5 stars
$6.27
-3.5%
$16.50
+163.2%
-3.6%$1.12B$10.01M-3.22330
SPRY
ARS Pharmaceuticals
3.0145 of 5 stars
$10.93
-3.4%
$33.80
+209.2%
-37.1%$1.12B$89.15M-22.3190Positive News
DNTH
Dianthus Therapeutics
2.9467 of 5 stars
$34.42
-0.1%
$61.57
+78.9%
+22.7%$1.11B$6.24M-10.5980
LENZ
LENZ Therapeutics
2.3677 of 5 stars
$38.61
-0.5%
$52.80
+36.8%
+36.7%$1.11BN/A-20.32110Analyst Forecast
Gap Up
AMPH
Amphastar Pharmaceuticals
4.7419 of 5 stars
$23.51
-0.5%
$31.60
+34.4%
-53.2%$1.10B$731.97M8.812,028Positive News
UPB
Upstream Bio
1.9856 of 5 stars
$20.08
+2.3%
$56.50
+181.4%
-19.0%$1.06B$2.37M0.0038

Related Companies and Tools


This page (NASDAQ:IMMP) was last updated on 10/20/2025 by MarketBeat.com Staff
From Our Partners